6 completed, 6 recruiting, 3 active not recruiting, 2 not yet recruiting. 9 Phase 2, 3 Phase 3, 2 Phase 1, 1 Not applicable.
Follow C3 Glomerulopathy: new trials by email Literature Review of C3 Glomerulopathy trials Research Report on C3 Glomerulopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Adult C3 Glomerulopathy Patients NM8074 - C3 Glomerulopathy | Phase 1 / Phase 2 | Not yet recruiting | NovelMed Therapeutics | 18 | 2027-05-01 | 2026-04-13 |
| A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy | Recruiting | Novartis Pharmaceuticals | 21 | 2026-06-15 | 2026-06-26 | |
| CHART-C3G/CLNP023B12011 Iptacopan - C3 Glomerulopathy, Complement-mediated Kidney Disease | Not yet recruiting | Novartis Pharmaceuticals | 83 | 2026-01-01 | 2026-01-09 | |
| Fabhalta Capsules Specified Drug-use Survey C3 Glomerulopathy | Active not recruiting | Novartis Pharmaceuticals | 33 | 2025-09-17 | 2026-07-13 | |
| A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases SGB-9768 - IgA Nephropathy (IgAN), C3 Glomerulopathy | Phase 2 | Active not recruiting | Suzhou Sanegene Bio Inc. | 45 | 2025-06-06 | 2026-09-04 |
| Home Reported Outcomes in C3G Study C3 Glomerulopathy | Recruiting | Novartis Pharmaceuticals | 100 | 2025-04-07 | 2025-06-19 | |
| Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN OMS906 study drug - C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis | Phase 2 | Recruiting | Omeros Corporation | 20 | 2024-03-01 | 2025-07-15 |
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan - C3G, IC-MPGN | Phase 3 | Active not recruiting | Apellis Pharmaceuticals, Inc. | 100 | 2023-05-29 | 2026-04-02 |
| Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease ARO-C3, Placebo - C3 Glomerulopathy, IgA Nephropathy | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 62 | 2022-02-01 | 2026-05-22 |
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan, Placebo - C3G, IC-MPGN | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 124 | 2021-11-12 | 2026-01-29 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Pegcetacoplan - C3G, IC-MPGN | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 13 | 2021-09-07 | 2026-04-21 |
| Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Aliskiren, Enalapril - C3 Glomerulopathy, Membranoproliferative Glomerulonephritis | Phase 2 | Recruiting | Region Skane | 30 | 2020-10-01 | 2025-06-22 |
| Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN LNP023 - C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis | Phase 3 | Recruiting | Novartis Pharmaceuticals | 225 | 2019-10-03 | 2026-08-07 |
| Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study Non contrast-enhanced magnetic resonance imaging - C3 Glomerulonephritis, C3 Glomerulopathy | Not applicable | Completed | Mario Negri Institute for Pharmacological Research | 7 | 2018-12-06 | 2021-11-26 |
| A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 Danicopan - C3 Glomerulonephritis, C3 Glomerulopathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 22 | 2018-06-20 | 2023-08-21 |
| A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) Danicopan, Placebo - C3 Glomerulopathy, C3 Glomerulonephritis | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2018-06-12 | 2022-10-14 |
| A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN Danicopan - C3 Glomerulonephritis, Dense Deposit Disease | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 6 | 2017-08-09 | 2021-11-04 |
| National Registry of Rare Kidney Diseases Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis | Recruiting | UK Kidney Association | 35000 | 2009-11-06 | 2023-10-04 | |
| C3G/Primary IC-MPGN EAP Pegcetacoplan - C3G, IC-MPGN | Approved for marketing | Apellis Pharmaceuticals, Inc. | 2025-11-06 |
Glomerulonephritis, Membranoproliferative (12) · Glomerulonephritis, IGA (3) · Proteinuria (2) · Adenine phosphoribosyltransferase deficiency (1) · Atypical Hemolytic Uremic Syndrome (1) · Bartter Syndrome (1) · Calciphylaxis (1) · Cystinosis (1) · Cystinuria (1) · Dent Disease (1) · Denys-Drash Syndrome (1) · Diabetes Insipidus, Nephrogenic (1) · Fabry Disease (1) · Fibromuscular Dysplasia (1) · Gitelman Syndrome (1)
Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Male Urogenital Diseases (15) · Urogenital Diseases (15) · Urologic Diseases (15) · Glomerulonephritis (14) · Immune System Diseases (14) · Kidney Diseases (14) · Nephritis (14) · Autoimmune Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Urination Disorders (3) · Anemia (2) · Anemia, Hemolytic (2) · Hematologic Diseases (2)
pegcetacoplan (4) · danicopan (3) · iptacopan (2) · Enalapril (1) · aliskiren (1) · rhoA GTP-Binding Protein (1)
Novartis Pharmaceuticals (5) · Apellis Pharmaceuticals, Inc. (4) · Alexion Pharmaceuticals, Inc. (3) · Arrowhead Pharmaceuticals (1) · Mario Negri Institute for Pharmacological Research (1) · NovelMed Therapeutics (1) · Omeros Corporation (1) · Region Skane (1) · Suzhou Sanegene Bio Inc. (1) · UK Kidney Association (1)
United Kingdom (8) · United States (7) · Australia (6) · Italy (6) · Netherlands (6) · Argentina (4) · Belgium (4) · Brazil (4) · France (4) · Japan (4) · South Korea (4) · Spain (4) · Switzerland (4) · Czechia (3) · Germany (3)
Diana Karpman (1) · Steve Whitaker, MD (1)
PMID 36423588, PMID 42133432, PMID 37926085, PMID 38299639, PMID 41337715
2023 (3), 2017 (2), 2016 (1), 2018 (1), 2019 (1)